Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
Résumé
In the version of this article initially published, the title of the paper, now reading "Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial," appeared incorrectly as "Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial.
Domaines
Médecine humaine et pathologieOrigine | Fichiers éditeurs autorisés sur une archive ouverte |
---|---|
licence |